Physician profile
Deepthi Krishna
NPI 1235910126
$3,036.63
in general payments reported to CMS, 2019-2025
24 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $845 · 2024: $1,028 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,805 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,804.66 |
| Education | $231.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $249.98 | 2024-2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $231.32 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.61 | 2024 | Xifaxan |
| Abbvie INC. | $195.38 | 2023-2025 | |
| Janssen Biotech, INC. | $190.69 | 2025 | Tremfya |
| Amgen INC. | $190.58 | 2025 | Krystexxa, Otezla, Evenity |
| Madrigal Pharmaceuticals | $147.24 | 2025 | Rezdiffra |
| Alnylam Pharmaceuticals INC. | $134.98 | 2025 | Givlaari |
| Hologic Sales and Service, LLC | $132.83 | 2024 | Aptima |
| Inspire Medical Systems, INC. | $126.80 | 2023 | Inspire |
| Tg Therapeutics, INC. | $125.00 | 2023 | |
| Novo Nordisk INC | $124.99 | 2023 | Wegovy |
| Alexion Pharmaceuticals, INC. | $124.99 | 2024 | |
| Csl Behring | $124.99 | 2024 | Hizentra |
| Pfizer INC. | $124.89 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $113.54 | 2023 | Ocaliva |
| Teva Pharmaceuticals USA, INC. | $111.15 | 2024 | Austedo Xr |
| Incyte Corporation | $110.73 | 2023 | Jakafi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $69.78 | 2025 | Saphnelo |
| Axsome Therapeutics, INC. | $35.00 | 2025 | Auvelity |
| Almatica Pharma LLC | $24.04 | 2025 | Loreev Xr, Teriparatide |
| Janssen Pharmaceuticals, INC | $19.81 | 2025 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $19.31 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepthi Krishna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.